Emerging Microbes and Infections (Jan 2021)
Pre-optimized phage therapy on secondary Acinetobacter baumannii infection in four critical COVID-19 patients
- Nannan Wu,
- Jia Dai,
- Mingquan Guo,
- Jianhui Li,
- Xin Zhou,
- Feng Li,
- Yuan Gao,
- Hongping Qu,
- Hongzhou Lu,
- Jing Jin,
- Tao Li,
- Lei Shi,
- Qingguo Wu,
- Ruoming Tan,
- Mingli Zhu,
- Lan Yang,
- Yun Ling,
- Shunpeng Xing,
- Jianzhong Zhang,
- Bangxin Yao,
- Shuai Le,
- Jingmin Gu,
- Jinhong Qin,
- Jie Li,
- Mengjun Cheng,
- Demeng Tan,
- Linlin Li,
- Yiyuan Zhang,
- Zhaoqin Zhu,
- Jinfeng Cai,
- Zhigang Song,
- Xiaokui Guo,
- Li-Kuang Chen,
- Tongyu Zhu
Affiliations
- Nannan Wu
- Shanghai Institute of Phage, Shanghai Public Health Clinical Center, Fudan University, Shanghai, People’s Republic of China
- Jia Dai
- Shanghai Institute of Phage, Shanghai Public Health Clinical Center, Fudan University, Shanghai, People’s Republic of China
- Mingquan Guo
- Shanghai Institute of Phage, Shanghai Public Health Clinical Center, Fudan University, Shanghai, People’s Republic of China
- Jianhui Li
- Shanghai Institute of Phage, Shanghai Public Health Clinical Center, Fudan University, Shanghai, People’s Republic of China
- Xin Zhou
- Shanghai Institute of Phage, Shanghai Public Health Clinical Center, Fudan University, Shanghai, People’s Republic of China
- Feng Li
- Department of Respiratory Medicine, Shanghai Public Health Clinical Center, Fudan University, Shanghai, People’s Republic of China
- Yuan Gao
- Department of Critical Care Medicine, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, People’s Republic of China
- Hongping Qu
- Department of Critical Care Medicine, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, People’s Republic of China
- Hongzhou Lu
- Department of Infectious Diseases and Immunology, Shanghai Public Health Clinical Center, Shanghai, People’s Republic of China
- Jing Jin
- Xituo Biotechnology Co., Ltd, Zhengzhou, People’s Republic of China
- Tao Li
- Department of Tuberculosis, Shanghai public health clinical center, Fudan University, Shanghai, People’s Republic of China
- Lei Shi
- Department of Hospital Infection Management, Shanghai Public Health Clinical Center, Fudan University, Shanghai, People’s Republic of China
- Qingguo Wu
- Department of Respiratory Medicine, Shanghai Public Health Clinical Center, Fudan University, Shanghai, People’s Republic of China
- Ruoming Tan
- Department of Critical Care Medicine, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, People’s Republic of China
- Mingli Zhu
- Department of Critical Care Medicine, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, People’s Republic of China
- Lan Yang
- Shanghai Institute of Phage, Shanghai Public Health Clinical Center, Fudan University, Shanghai, People’s Republic of China
- Yun Ling
- Department of Infectious Disease, Shanghai Public Health Clinical Center, Fudan University, Shanghai, People’s Republic of China
- Shunpeng Xing
- Department of Critical Care Medicine, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, People’s Republic of China
- Jianzhong Zhang
- Department of Pharmacy, Zhongshan Hospital Fudan University, Shanghai, People’s Republic of China
- Bangxin Yao
- Department of Pharmacy, Zhongshan Hospital Fudan University, Shanghai, People’s Republic of China
- Shuai Le
- Shanghai Institute of Phage, Shanghai Public Health Clinical Center, Fudan University, Shanghai, People’s Republic of China
- Jingmin Gu
- Shanghai Institute of Phage, Shanghai Public Health Clinical Center, Fudan University, Shanghai, People’s Republic of China
- Jinhong Qin
- Shanghai Institute of Phage, Shanghai Public Health Clinical Center, Fudan University, Shanghai, People’s Republic of China
- Jie Li
- Shanghai Institute of Phage, Shanghai Public Health Clinical Center, Fudan University, Shanghai, People’s Republic of China
- Mengjun Cheng
- Shanghai Institute of Phage, Shanghai Public Health Clinical Center, Fudan University, Shanghai, People’s Republic of China
- Demeng Tan
- Shanghai Institute of Phage, Shanghai Public Health Clinical Center, Fudan University, Shanghai, People’s Republic of China
- Linlin Li
- Shanghai Institute of Phage, Shanghai Public Health Clinical Center, Fudan University, Shanghai, People’s Republic of China
- Yiyuan Zhang
- Shanghai Institute of Phage, Shanghai Public Health Clinical Center, Fudan University, Shanghai, People’s Republic of China
- Zhaoqin Zhu
- Department of Laboratory Medicine, Shanghai Public Health Clinical Center, Fudan University, Shanghai, People’s Republic of China
- Jinfeng Cai
- Department of Laboratory Medicine, Shanghai Public Health Clinical Center, Fudan University, Shanghai, People’s Republic of China
- Zhigang Song
- Department of Pathogen Diagnosis and Biosafety, Shanghai Public Health Clinical Center, Shanghai, People’s Republic of China
- Xiaokui Guo
- Shanghai Institute of Phage, Shanghai Public Health Clinical Center, Fudan University, Shanghai, People’s Republic of China
- Li-Kuang Chen
- Shanghai Institute of Phage, Shanghai Public Health Clinical Center, Fudan University, Shanghai, People’s Republic of China
- Tongyu Zhu
- Shanghai Institute of Phage, Shanghai Public Health Clinical Center, Fudan University, Shanghai, People’s Republic of China
- DOI
- https://doi.org/10.1080/22221751.2021.1902754
- Journal volume & issue
-
Vol. 10,
no. 1
pp. 612 – 618
Abstract
Phage therapy is recognized as a promising alternative to antibiotics in treating pulmonary bacterial infections, however, its use has not been reported for treating secondary bacterial infections during virus pandemics such as coronavirus disease 2019 (COVID-19). We enrolled 4 patients hospitalized with critical COVID-19 and pulmonary carbapenem-resistant Acinetobacter baumannii (CRAB) infections to compassionate phage therapy (at 2 successive doses of 109 plaque-forming unit phages). All patients in our COVID-19-specific intensive care unit (ICU) with CRAB positive in bronchoalveolar lavage fluid or sputum samples were eligible for study inclusion if antibiotic treatment failed to eradicate their CRAB infections. While phage susceptibility testing revealed an identical profile of CRAB strains from these patients, treatment with a pre-optimized 2-phage cocktail was associated with reduced CRAB burdens. Our results suggest the potential of phages on rapid responses to secondary CRAB outbreak in COVID-19 patients.
Keywords
